Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 2/3 1

Status

Completed 9Active not recruiting 7Recruiting 4Unknown 2Terminated 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Non-Small Cell Lung Cancer With HER2- Mutations 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × CP protocol × Clear all
NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

NCT04460352 2025-03-06

NEEDS

Karolinska University Hospital

Phase 3 Recruiting
1,020 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06008106 2024-06-28

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Dermatologic

Melanoma

NCT04137653 2021-07-20

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Shengjing Hospital

Phase 3 Recruiting
1,498 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡